Teladoc, Inc. (NYSE:TDOC) VP Mark Hirschhorn sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, September 22nd. The shares were sold at an average price of $31.93, for a total transaction of $798,250.00. Following the completion of the sale, the vice president now directly owns 64,987 shares in the company, valued at approximately $2,075,034.91. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Teladoc, Inc. (TDOC) opened at 31.35 on Thursday. The stock’s market capitalization is $1.78 billion. The firm has a 50-day moving average of $34.32 and a 200 day moving average of $34.32. Teladoc, Inc. has a 52 week low of $14.00 and a 52 week high of $37.55.

Teladoc (NYSE:TDOC) last announced its earnings results on Wednesday, August 2nd. The health services provider reported ($0.28) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.26) by ($0.02). Teladoc had a negative net margin of 47.75% and a negative return on equity of 19.88%. The business had revenue of $44.60 million during the quarter, compared to analyst estimates of $44.39 million. During the same period in the previous year, the company earned ($0.38) earnings per share. The business’s revenue for the quarter was up 68.3% on a year-over-year basis. On average, analysts anticipate that Teladoc, Inc. will post ($1.44) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Teladoc, Inc. (TDOC) VP Sells $798,250.00 in Stock” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The original version of this piece of content can be read at https://www.thecerbatgem.com/2017/09/28/teladoc-inc-tdoc-vp-sells-798250-00-in-stock.html.

Several institutional investors and hedge funds have recently made changes to their positions in the business. Ameritas Investment Partners Inc. raised its position in shares of Teladoc by 134.2% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,724 shares of the health services provider’s stock valued at $164,000 after purchasing an additional 2,707 shares in the last quarter. California State Teachers Retirement System raised its position in shares of Teladoc by 101.9% in the 2nd quarter. California State Teachers Retirement System now owns 95,321 shares of the health services provider’s stock valued at $3,308,000 after purchasing an additional 48,112 shares in the last quarter. Raymond James Financial Services Advisors Inc. acquired a new position in shares of Teladoc in the 2nd quarter valued at approximately $202,000. The Manufacturers Life Insurance Company raised its position in shares of Teladoc by 132.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 41,270 shares of the health services provider’s stock valued at $1,432,000 after purchasing an additional 23,553 shares in the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new position in shares of Teladoc in the 2nd quarter valued at approximately $2,316,000.

Several analysts recently weighed in on TDOC shares. Canaccord Genuity reaffirmed a “buy” rating and issued a $42.00 target price (up previously from $34.00) on shares of Teladoc in a report on Tuesday, June 20th. Chardan Capital increased their price target on shares of Teladoc from $30.00 to $41.00 and gave the company a “buy” rating in a research note on Tuesday, June 20th. Piper Jaffray Companies reiterated a “buy” rating and issued a $32.00 price target on shares of Teladoc in a research note on Friday, July 14th. KeyCorp reiterated a “buy” rating and issued a $37.00 price target on shares of Teladoc in a research note on Sunday, September 17th. Finally, TheStreet lowered shares of Teladoc from a “c-” rating to a “d” rating in a research note on Monday, July 3rd. Five equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $36.18.

Teladoc Company Profile

Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.

Insider Buying and Selling by Quarter for Teladoc (NYSE:TDOC)

Receive News & Stock Ratings for Teladoc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Inc. and related stocks with our FREE daily email newsletter.